Anti-VEGF antibody bevacizumab (Avastin) with 5FU/LV as third line treatment for colorectal cancer.

Emmanouilides, C; Pegram, M; Robinson, R; Hecht, R; Kabbinavar, F; Isacoff, W

Emmanouilides, C; Pegram, M; Robinson, R; Hecht, R; Kabbinavar, F; Isacoff, W.

Affiliation

Emmanouilides C; Division of Hematology/Oncology, UCLA Medical Center, Los Angeles, CA 90095, USA. cemmanou@mednet.ucla.edu

Tech Coloproctol ; 8 Suppl 1: s50-2, 2004 Nov.

Article de En | MEDLINE | ID: mdl-15655642

Sujet(s)

Recherche sur Google

Ajouter à My VHL

Imprimer

XML

PubMed Links

Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs colorectales / Leucovorine / Thérapie de rattrapage / Fluorouracil / Anticorps monoclonaux Type d'étude: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limites: Aged / Female / Humans / Male / Middle aged Langue: En Journal: Tech Coloproctol Sujet du journal: GASTROENTEROLOGIA Année: 2004 Type de document: Article Pays d'affiliation: États-Unis d'Amérique

Recherche sur Google

Ajouter à My VHL

Imprimer

XML

PubMed Links